CD19 CAR-T细胞治疗后出现类似噬血细胞性淋巴组织细胞增多症的毒性(carHLH)
carHLH需多药免疫调节治疗且反应不一;
要点
- carHLH需高度怀疑并按多药免疫调节治疗。
研究设计与样本
- 研究报告接受CD19特异性CAR-T细胞治疗的儿童和年轻成人中carHLH的发生情况。
主要发现
- carHLH诊断需高度怀疑,治疗采用多药免疫调节,不同疗法反应不一。
临床怎么用
- 对CD19 CAR-T治疗后高疾病负荷患者应高度警惕carHLH,及时诊断并予多药免疫调节治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR T-cell) therapy is associated with significant toxicities secondary to immune activation, including a rare but increasingly recognised severe toxicity resembling haemophagocytic lymphohistiocytosis (carHLH). We report the development of carHLH in 14·8% of paediatric patients and young adults treated with CD19-specific CAR T-cell therapy with carHLH, occurring most commonly in those with high disease burden. The diagnosis and treatment of carHLH required a high index of suspicion and included multidrug immunomodulation with variable response to therapies. Compared to patients without carHLH, patients with carHLH had both reduced response to CAR T-cell therapy (P-value = 0·018) and overall survival (P-value = < 0·0001).
引用
- Hines MR, Keenan C, Maron Alfaro G, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021. PMID: 34263927. doi:10.1111/bjh.17662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。